PHAS News and Press, PhaseBio Pharmaceuticals Inc. From 06/17/21

Agreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab opportunity Establishes...

Study leveraging the IBM® MarketScan® claims database examined healthcare resource utilization including total healthcare costs and bleeding costs in patients initiating P2Y 12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y...

Study leveraging the IBM® MarketScan® claims database examined bleeding events and rates of surgical procedures in patients initiating P2Y 12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y 12 inhibitors had a higher bur...

PhaseBio Pharmaceuticals (PHAS): Q1 GAAP EPS of -$0.87 misses by $0.14.Revenue of $0M misses by $0.02M.Press Release For further details see: PhaseBio Pharmaceuticals EPS misses by $0.14, misses on revenue

Continued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab Completed underwritten public offering of common stoc...

The following slide deck was published by PhaseBio Pharmaceuticals, Inc. in conjunction with this event. For further details see: PhaseBio Pharmaceuticals (PHAS) Investor Presentation - Slideshow

Today, we peak back in on PhaseBio for the first time since late 2019. The company recently addressed near-term funding needs and is advancing its primary candidate towards potential FDA approval in 2022. A full analysis follows in the paragraphs below. For further details s...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the ...

Translate Bio (TBIO) -26% after Translate Bio’s Cystic Fibrosis therapy fails to improve lung function in Phase 1/2 trial.PhaseBio Pharmaceuticals (PHAS) -14% on equity raise.Broadway Financial (BYFC) -13% after stockholders of Broadway Financial and CFBan...

PhaseBio Pharmaceuticals (PHAS) -14% premarket after pricing 16M common stock at $3.50/share, for gross proceeds of ~$56M.Underwriters' over-allotment an additional 2.4M shares.Offering is expected to close on March 22. For further details see: PhaseBio shares down on equity r...